

Aims


Marlborough Special Situations is a cell of Marlborough International Fund PCC Limited, a Class B collective investment scheme authorised by the Guernsey Financial Services Commission. The investment objective of the Cell is primarily to achieve capital growth by acting as a feeder fund into the Marlborough Special Situations Fund, a UCITS fund authorised by the Financial Conduct Authority. All portfolio and performance data relates to the master fund.

Philosophy

The investment philosophy is premised upon the fact that UK smaller companies tend to outperform their larger counterparts over the long term. By conducting its own primary research the investment team believes it can exploit the market information shortfalls and inefficiencies associated with small cap analysis.

Performance - Master Fund, GBP

All performance data relates to GBP shares. USD and EUR share classes are unhedged.



Source: Morningstar Direct

| | 1 year | 3 years | 5 years | 10 years | Since Mgr appt |
|-----------------------------------|--------|---------|---------|----------|----------------|
| Master Fund GBP | 4.0% | 12.9% | 50.9% | 265.8% | 2,721.2% |
| IA UK Smaller Co's Sector Average | 7.5% | 20.6% | 53.2% | 214.0% | 469.2% |
| FTSE All-Share Index | -1.4% | 4.7% | 19.1% | 93.0% | 177.4% |

All performance data as at 29/02/2020. Source: Morningstar, bid-bid, GBP, Net Inc reinvested.

The Marlborough Special Situations Fund is the top performer of all UK authorised Unit Trust/OEICs investing in UK equities since Giles Hargreave was appointed investment adviser in July 1998.

To view additional portfolio information visit:

<http://funds.marlboroughfunds.com/doc/B659XQ0/factsheet.pdf>

Process

The portfolio is constructed primarily on a bottom-up basis. However the team is not solely driven by bottom-up factors, there is a macro-economic consensus within the team which generates top-down drivers to the creation of the portfolio.


Investment Adviser

The expertise of the investment managers, Giles Hargreave and Eustace Santa Barbara, and their team are the major contributors to the fund's outperformance.

The ten-strong investment team has in excess of 200 years' market experience. The size and experience of the team allows them to effectively evaluate a broad range of companies, many of which are out of scope for other research teams. The team meets an average of 25 companies each week.

This breadth of resource allows the managers to construct a diversified portfolio of over c.140 holdings. Stock-specific risk is controlled by taking relatively small initial positions and then 'averaging up' as the company management delivers on plans. The maximum position size is usually no more than 2 - 2.4%.

Investment Team Organisation



Key Points

- Intensive primary research of small cap companies to gain competitive advantage
- Diversified portfolio of over c.140 holdings to reduce stock-specific risk and volatility
- Excellent long term track record.

Master Fund Ratings



| | |
|-----------------------------------|---|
| Initial Charge: | 5.0% |
| Total Expense Ratio (TER): | 1.37% |
| Identification Codes: | GBP Sedol: BWX5H04, ISIN: GG00BWX5H049 |
| (C Class Shares) | EUR (unhedged) Sedol: BWX5H26, ISIN: GG00BWX5H262 USD (unhedged) Sedol: BWX5H15, ISIN: GG00BWX5H155 |
| Manager Details: | Marlborough International Management Limited, Town Mills South, La Rue du Pre, St Peter Port, Guernsey, GY1 3HZ |
| Administrator: | Louvre Fund Services Limited, First Floor, St Peter's House, Le Bordage, St Peter Port Guernsey, GY1 1BR |

This information is for Financial Advisers only and should not be relied upon by Retail Investors. The past is not necessarily a guide to future performance. Investments and the income derived from them can fall as well as rise and the investor may not get back the amount originally invested. Data as at 02/03/2020.

Top 10 Holdings 02/03/2020

| Name | % Weight |
|------------------------|----------|
| S4 Capital | 2.4 |
| Caretech Holdings | 1.9 |
| CVS Group | 1.9 |
| SDL | 1.8 |
| XP Power | 1.6 |
| Draper Esprit | 1.5 |
| Grainger | 1.5 |
| Spirent Communications | 1.5 |
| Creo Medical Group | 1.5 |
| Syncona | 1.5 |

Monthly Fund Commentary

To view the master fund commentary [click here](#) or visit www.marlboroughfunds.com

This information is for Financial Advisers only and should not be relied upon by Retail Investors. The Special Situations Cell referred to is a cell of Marlborough International PCC Limited (the 'Company'), a protected cell company incorporated in Guernsey and authorised as a Class B Collective Investment Scheme under the terms of the Protection of Investors (Bailiwick of Guernsey) law, 1987, as amended. Investment may only be made on the basis of the current Prospectus. The following is a summary only of some key items in the Prospectus. Investors in Protected Cell Company (PCC) must have the financial expertise and willingness to accept the risks inherent in this investment. These risks include inter alia, the fact that neither the past performance nor operating history of the Company is a guarantee of future performance. It should be appreciated that the value of Shares is not guaranteed and may go down as well as up and that investors may not receive, on redemption of their Shares, the amount that they originally invested. Investors should consult their professional advisers about the consequences to them, and inform themselves of the legal requirements for, acquiring, holding, exchanging redeeming or disposing of Shares under the relevant laws of the jurisdictions to which they are subject, including any tax consequences, exchange control requirements, requisite governmental or other consents and any other formalities. If you are in any doubt about the action you should take, you should consult a suitably qualified and licensed or authorised professional adviser who specialises in advising on the acquisition of shares and other securities. Investment in the Company should only be undertaken as part of a diversified investment portfolio. Investment in the Shares should be viewed as a medium term investment. Shares may not be redeemed otherwise than on any Dealing Day. The Shares of the Company are not listed on any stock exchange and it is not anticipated that there will be any secondary market in the Shares. The Marlborough Special Situations Fund invests in smaller companies which carry a higher degree of risk than larger companies. The shares of smaller companies may be less liquid and their performance more volatile over shorter time periods. The Fund invests mainly in the UK. Therefore it may be more vulnerable to market sentiment in that country.

This fact sheet contains FTSE data. Source: FTSE International Limited ("FTSE") © FTSE 2020. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under licence. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent. Data accurate as of 02/03/2020.